AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17038636 — intervention group
Group type: COMPARATOR
Intervention: AHA step 1 diet alone
Number of subjects: 70
Study 12527538 — intervention group
Group type: EXPERIMENTAL
Intervention: MED+DBT
Number of subjects: 34
Study 12527538 — intervention group
Group type: COMPARATOR
Intervention: MED
Number of subjects: 34
Study 11286606 — intervention group
Group type: EXPERIMENTAL
Intervention: Test brand (sugar-coated chloroquine)
Number of subjects: 20
Study 11286606 — intervention group
Group type: COMPARATOR
Intervention: Control chloroquine phosphate
Number of subjects: 20
Study 11286606 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 9210109 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer reading treatment
Number of subjects: 55
Study 9210109 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer stimulation
Number of subjects: 55
Study 9210109 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 55
Study 7965443 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected (hemiplegic) side
Number of subjects: 19
Study 7965443 — intervention group
Group type: COMPARATOR
Intervention: Unaffected (control) side
Number of subjects: 19
Study 3277904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent chlorambucil once a month
Number of subjects: 59
Study 3277904 — intervention group
Group type: COMPARATOR
Intervention: No treatment (observation)
Number of subjects: 59
Study 30466334 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced exercise (n = 30)
Number of subjects: 59
Study 30466334 — intervention group
Group type: COMPARATOR
Intervention: Prescribed moderate-intensity exercise (n = 29)
Number of subjects: 59
Study 31218770 — intervention group
Group type: EXPERIMENTAL
Intervention: SVN-2B plus IFNβ
Number of subjects: 83
Study 31218770 — intervention group
Group type: EXPERIMENTAL
Intervention: SVN-2B
Number of subjects: 83
Study 31218770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 31218770 — intervention group
Group type: EXPERIMENTAL
Intervention: SVN-2B plus IFNβ (Step 2)
Number of subjects: 83
Study 29275607 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.5 mg/kg in 250 ml of 0.9% normal saline for 1 hour daily for 7 days)
Number of subjects: 66
Study 29275607 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.9% normal saline infusion)
Number of subjects: 66
Study 29275607 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 66
Study 29275607 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 25010823 — intervention group
Group type: EXPERIMENTAL
Intervention: HME1L (Heat and Moisture Exchanger with low fresh gas flow 1 L·min)
Number of subjects: 40
Study 25010823 — intervention group
Group type: EXPERIMENTAL
Intervention: HME3L (Heat and Moisture Exchanger with high fresh gas flow 3 L·min)
Number of subjects: 40
Study 25010823 — intervention group
Group type: COMPARATOR
Intervention: 1L (No Heat and Moisture Exchanger with low fresh gas flow 1 L·min)
Number of subjects: 40
Study 25010823 — intervention group
Group type: COMPARATOR
Intervention: 3L (No Heat and Moisture Exchanger with high fresh gas flow 3 L·min)
Number of subjects: 40
Study 21870208 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous decompression (PD)
Number of subjects: 36
Study 20137805 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week streptomycin (15 mg/kg once daily) and oral rifampicin (10 mg/kg once daily) for 8 weeks
Number of subjects: 151
Study 20137805 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week streptomycin (15 mg/kg once daily) and oral rifampicin (10 mg/kg once daily) for 4 weeks followed by rifampicin and clarithromycin (7.5 mg/kg once daily) for 4 weeks
Number of subjects: 151
Study 17645253 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with medication
Number of subjects: 60
Study 17645253 — intervention group
Group type: COMPARATOR
Intervention: Simple acupuncture (Control Group I)
Number of subjects: 60
Study 17645253 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Bushen Capsules (Control Group II)
Number of subjects: 60
Study 16098615 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic Ems Mineral Salts (EMS) solution (1-2 sprays into each nostril t.d. for 14 days)
Number of subjects: 66
Study 16098615 — intervention group
Group type: COMPARATOR
Intervention: Xylometazoline solution (0.05%) (1-2 sprays into each nostril t.d. for 14 days)
Number of subjects: 66
Study 11871957 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape feedback during simulations
Number of subjects: 32
Study 11871957 — intervention group
Group type: COMPARATOR
Intervention: Control group (no videotape feedback)
Number of subjects: 32
Study 10449020 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study 10449020 — intervention group
Group type: EXPERIMENTAL
Intervention: Exceed
Number of subjects: 10
Study 10449020 — intervention group
Group type: EXPERIMENTAL
Intervention: Decarbonated Coca-Cola
Number of subjects: 10
Study 10449020 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic solution of lactulose
Number of subjects: 10
Study 10449020 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical maneuvers (bending forward, tightening abdominal muscles, tightening a belt, breathing through pursed lips)
Number of subjects: 10
Study 10449020 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing abdominal muscles or increasing the impact of foot strike
Number of subjects: 10
Study 7595984 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyostimulation (EMS)
Number of subjects: 12
Study 7595984 — intervention group
Group type: COMPARATOR
Intervention: Concentric exercise (CONC)
Number of subjects: 12
Study 2220621 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 201
Study 2220621 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 201
Study 2220621 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepindolol
Number of subjects: 201
Study 2220621 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 201
Study 2220621 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers and enalapril
Number of subjects: 201
Study 7194082 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY g 5421 (3 x 100 mg)
Number of subjects: 10
Study 7194082 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY g 5421 (6 x 50 mg)
Number of subjects: 10
Study 7194082 — intervention group
Group type: COMPARATOR
Intervention: Insulin, glucagon, lactate, triglyceride concentration (Control)
Number of subjects: 10
Study 7194082 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY g 5421
Number of subjects: 10
Study 31270901 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Number of subjects: 36
Study 31270901 — intervention group
Group type: COMPARATOR
Intervention: 3% Sodium hypochlorite
Number of subjects: 36
Study 31270901 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 36
Study 29998767 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free latanoprost
Number of subjects: 140
Study 28342682 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week home program comprising progressive resistance strength training, movement strategy training and falls education
Number of subjects: 133
Study 28342682 — intervention group
Group type: COMPARATOR
Intervention: 6 weeks of non-specific life skills training (Control)
Number of subjects: 133
Study 25431105 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure treatment (adherent patients)
Number of subjects: 822
Study 25431105 — intervention group
Group type: COMPARATOR
Intervention: Positive airway pressure treatment (non-users)
Number of subjects: 822
Study 25431105 — intervention group
Group type: COMPARATOR
Intervention: General population (n = 742)
Number of subjects: 822
Study 23420314 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis combined with local bath-PUVA therapy
Number of subjects: 48
Study 23420314 — intervention group
Group type: COMPARATOR
Intervention: Local PUVA therapy
Number of subjects: 48
Study 23420314 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone (corticosteroid)
Number of subjects: 48
Study 21276366 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-open group (hinge at the inner margin of the lateral mass)
Number of subjects: 102
Study 21276366 — intervention group
Group type: COMPARATOR
Intervention: Narrow-open group (hinge at the lamina margin)
Number of subjects: 102
Study 19155203 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel in combination with doxorubicin and cyclophosphamide (TAC)
Number of subjects: 0
Study 19155203 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)
Number of subjects: 0
Study 17382828 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 716
Study 17173263 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis doses prescribed based on empirical criteria and urea kinetics model
Number of subjects: 0
Study 12727944 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopanoic acid (group A)
Number of subjects: 12
Study 12727944 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (group B)
Number of subjects: 12
Study 10565811 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 16
Study 10565811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 16
Study 10565811 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 16
Study 10565811 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 16
Study 8605634 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (an angiotensin-converting enzyme inhibitor)
Number of subjects: 9000
Study 8605634 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (a naturally occurring antioxidant vitamin)
Number of subjects: 9000
Study 1835959 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatril (200 mg) on low sodium diet (10 mmol/day)
Number of subjects: 8
Study 1835959 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatril (200 mg) on high sodium diet (350 mmol/day)
Number of subjects: 8
Study 1835959 — intervention group
Group type: COMPARATOR
Intervention: Placebo on low sodium diet (10 mmol/day)
Number of subjects: 8
Study 1835959 — intervention group
Group type: COMPARATOR
Intervention: Placebo on high sodium diet (350 mmol/day)
Number of subjects: 8
Study 7104144 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.18 mg/kg i.v.)
Number of subjects: 8
Study 7104144 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (0.023 mg/kg i.v.)
Number of subjects: 8
Study 7104144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31427299 — intervention group
Group type: EXPERIMENTAL
Intervention: VL-2397 (3 mg to 1,200 mg single intravenous doses)
Number of subjects: 0
Study 31427299 — intervention group
Group type: EXPERIMENTAL
Intervention: VL-2397 (300, 600, and 1,200 mg intravenous doses every 24 hours for 7 days)
Number of subjects: 0
Study 31427299 — intervention group
Group type: EXPERIMENTAL
Intervention: VL-2397 (single doses >30 mg)
Number of subjects: 0
Study 31427299 — intervention group
Group type: EXPERIMENTAL
Intervention: VL-2397 (overall and maximum exposures)
Number of subjects: 0
Study 31427299 — intervention group
Group type: EXPERIMENTAL
Intervention: VL-2397 (safety profile)
Number of subjects: 0
Study 30580349 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (lactobacillus rhamnosus 35) at a dose of 0.8 mg in infants >1500 gms and 0.4 mg in infants <1500 gms in 2 ml of expressed breast milk two times daily
Number of subjects: 72
Study 30580349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (expressed breast milk without probiotics)
Number of subjects: 72
Study 30580349 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (lactobacillus rhamnosus 35)
Number of subjects: 72
Study 25603000 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanate (40mg/kg per day for 7 days)
Number of subjects: 84
Study 23852661 — intervention group
Group type: EXPERIMENTAL
Intervention: Core decompression and isolated mononuclear cells (group A)
Number of subjects: 40
Study 23852661 — intervention group
Group type: COMPARATOR
Intervention: Core decompression and unprocessed bone marrow injection (group B)
Number of subjects: 40
Study 21245476 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic assisted consent (standard form-based informed consent plus a commercial interactive learning module)
Number of subjects: 101
Study 21245476 — intervention group
Group type: COMPARATOR
Intervention: Standard form-based informed consent
Number of subjects: 101
Study 21245476 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic assisted consent
Number of subjects: 101
Study 19224775 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol
Number of subjects: 175
Study 19224775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 16846090 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical activation with 3 consecutive 40-/microsec pulses of 1.5 kV/cm direct electrical current in buffer solution
Number of subjects: 100
Study 16846090 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electrical activation)
Number of subjects: 100
Study 14979308 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care
Number of subjects: 23828
Study 14979308 — intervention group
Group type: COMPARATOR
Intervention: Enhanced referral care
Number of subjects: 23828
Study 10992303 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mmol/kg Gadovist 1.0
Number of subjects: 89
Study 10992303 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mmol/kg Gadovist 1.0
Number of subjects: 89
Study 10992303 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 to 0.5 mmol/kg Gadovist 1.0
Number of subjects: 89
Study 10992303 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadovist 1.0
Number of subjects: 89
Study 9489070 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sustained-released 75 mg tablets taken b.i.d.
Number of subjects: 294
Study 9489070 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac enteric-coated 50 mg tablets given t.i.d.
Number of subjects: 294
Study 9489070 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sustained-released 75 mg tablets
Number of subjects: 294
Study 9489070 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac enteric-coated 50 mg tablets
Number of subjects: 294
Study 8251281 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram 1.5 mg kg‐1
Number of subjects: 60
Study 8251281 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 0.33 mg kg‐1
Number of subjects: 60
Study 8251281 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study 3885760 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 37
Study 3885760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 30283171 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melatonin 3 mg (2 tablets)
Number of subjects: 90
Study 30283171 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alprazolam 0.25 mg (2 tablets)
Number of subjects: 90
Study 30283171 — intervention group
Group type: COMPARATOR
Intervention: Placebo (multivitamin tablet 2 tablets)
Number of subjects: 90
Study 27376373 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) intravenous/subcutaneous
Number of subjects: 0
Study 27376373 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 0
Study 27376373 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 0
Study 27376373 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) subcutaneous
Number of subjects: 0
Study 27376373 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) intravenous
Number of subjects: 0
Study 24678896 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC (Computed Tomography Colonography)
Number of subjects: 20000
Study 24678896 — intervention group
Group type: COMPARATOR
Intervention: FS (Flexible Sigmoidoscopy)
Number of subjects: 20000
Study 24678896 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC
Number of subjects: 20000
Study 24678896 — intervention group
Group type: COMPARATOR
Intervention: FS
Number of subjects: 20000
Study 24352089 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg Breakfast (EB, n = 39)
Number of subjects: 73
Study 24352089 — intervention group
Group type: COMPARATOR
Intervention: Non-Egg Breakfast (NEB, n = 34)
Number of subjects: 73
Study 24352089 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg Breakfast (EB)
Number of subjects: 73
Study 24352089 — intervention group
Group type: COMPARATOR
Intervention: Non-Egg Breakfast (NEB)
Number of subjects: 73
Study 24352089 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 73
Study 20595484 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nanofiber nitric oxide (NO) releasing patch (NOP)
Number of subjects: 0
Study 20595484 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular meglumine antimoniate (Glucantime)
Number of subjects: 0
Study 18381542 — intervention group
Group type: EXPERIMENTAL
Intervention: Multinutrient fortifier added to human milk for 12 weeks after discharge
Number of subjects: 39
Study 18381542 — intervention group
Group type: COMPARATOR
Intervention: Unfortified human milk
Number of subjects: 39
Study 16627409 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BVP)
Number of subjects: 10
Study 16627409 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular pacing (RVP)
Number of subjects: 10
Study 14732966 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of arnica and hydroxyethyl salicylate (HES) in ethanolic solution (Sportino Acute Spray)
Number of subjects: 0
Study 14732966 — intervention group
Group type: COMPARATOR
Intervention: Arnica
Number of subjects: 0
Study 14732966 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl salicylate (HES)
Number of subjects: 0
Study 14732966 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (vehicle)
Number of subjects: 0
Study 14732966 — intervention group
Group type: COMPARATOR
Intervention: Water (reference substance)
Number of subjects: 0
Study 12799598 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy
Number of subjects: 28
Study 12799598 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Number of subjects: 28
Study 10484218 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Cholangiopancreatography (MRCP)
Number of subjects: 100
Study 10484218 — intervention group
Group type: COMPARATOR
Intervention: Direct cholangiography (ERCP, PTC, intraoperative cholangiography)
Number of subjects: 100
Study 7806733 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Status Questionnaire (FSQ)
Number of subjects: 83
Study 7806733 — intervention group
Group type: EXPERIMENTAL
Intervention: Katz Activities of Daily Living (ADL)
Number of subjects: 83
Study 7806733 — intervention group
Group type: EXPERIMENTAL
Intervention: Older Americans Resources and Services Instrumental Activities of Daily Living (OARS-IADL)
Number of subjects: 83
Study 7806733 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Performance Test (PPT)
Number of subjects: 83
Study 7806733 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Outcomes Study SF-36
Number of subjects: 83
Study 1786052 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine (6 micrograms/kg)
Number of subjects: 60
Study 1786052 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (4 micrograms/kg)
Number of subjects: 60
Study 1786052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7154618 — intervention group
Group type: EXPERIMENTAL
Intervention: muzolimine (loop-diuretic) for 6 weeks
Number of subjects: 18
Study 31337609 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell retinopathy (SCR) patients
Number of subjects: 52
Study 30659924 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-tailored lansoprazole daily for 24 weeks
Number of subjects: 0
Study 30659924 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dosing of open-label oral lansoprazole
Number of subjects: 0
Study 30659924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28487294 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets from high-responder donors
Number of subjects: 100
Study 28487294 — intervention group
Group type: COMPARATOR
Intervention: Platelets from low-responder donors
Number of subjects: 100
Study 26728633 — intervention group
Group type: EXPERIMENTAL
Intervention: SibworkS programme (six-week manual-based, cognitive-behavioural group programme)
Number of subjects: 36
Study 26728633 — intervention group
Group type: EXPERIMENTAL
Intervention: SibworkS programme
Number of subjects: 36
Study 24002343 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 28) completed a graded four-stage exercise protocol on a stationary bicycle (100 W × 5 min; 150 W × 5 min; 200 W × 5 min; sprint × 2 min)
Number of subjects: 42
Study 24002343 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 14) tested at identical periods without exercising
Number of subjects: 42
Study 21739168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide 2000 mg i.v. twice weekly after surgery
Number of subjects: 30
Study 21739168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide 500 mg i.v. (day -8, -4, -1)
Number of subjects: 30
Study 21739168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide 2000 mg i.v. (day -8, -4, -1)
Number of subjects: 30
Study 21739168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide (as a single agent)
Number of subjects: 30
Study 19409340 — intervention group
Group type: EXPERIMENTAL
Intervention: Early orthodontic treatment using Twin-block appliance
Number of subjects: 40
Study 19409340 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 40
Study 17443132 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (7.5 mg) + Placebo (P)
Number of subjects: 6
Study 17443132 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg) or (500 mg) + Zolpidem (7.5 mg)
Number of subjects: 6